1. Scrip
  2. >>R&D

Uncertainty Looms For Ziopharm After Patient Death

 
• By Lisa LaMotta

A death was reported in the company's early-stage gene therapy trial. It has not been determined yet whether the death was related to the drug and what the next steps for the company are.

chemistry

Ziopharm Oncology Inc. has had its share of trying times over the last three years as it lost a lead candidate and had to shift gears. But a wrench has been thrown into those plans as well after the company discloses a death in a recent early-stage study of its gene therapy.

The Boston-based biotech disclosed in a slide during a meeting presentation on July 14 that a third patient has died...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from R&D

More from Scrip

In Brief: PolyPid’s D-PLEX100 Aces Phase III Trial, US Partner, Submission Eyed

 
• By Sushmita Panda

PolyPid's D-PLEX100 meets Phase III endpoints this time around, significantly reducing surgical point infections in abdominal colorectal surgery, and is set for a US approval submission early next year.

Insmed’s PAH Data Indicate Potential To Surpass Established Therapies

 
• By Joseph Haas

Insmed’s inhaled treprostinil exceeded goals for reducing pulmonary vascular resistance and improving six-minute walk test distance in Phase IIb data.

NewAmsterdam’s CETP Inhibitor Improves Alzheimer’s Biomarkers

 
• By Mandy Jackson

Data from the BROADWAY trial testing LDL-C reduction in adults with ASCVD showed that obicetrapib improved Alzheimer’s disease biomarkers, including tau and amyloid. Analysts think the data could differentiate obicetrapib against competitors in the cholesterol market.